

This article was originally published [here](#)

Velocity Pharmaceutical Development, along with Dr John Nestor, had established Spitfire for the development of SP-1373, a potent GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH). Under the

The post [Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma](#) appeared first on [Pharmaceutical Business review](#).